Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
FATP
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "FATP" in MCE Product Catalog:
9
9 Publications Verification
Lipofermata is a fatty acid transport protein 2 (FATP2) inhibitor. Lipofermata shows fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. Lipofermata, an analog of spiro-indoline-thadiazole, shows zinc-specific suppression of antibacterial activity. Lipofermata perturbs zinc homeostasis in E. coli K-12 with a MIC of 16 μM .
5
5 Cited Publications
Art. -Nr.: HY-N0401A
CAS. Nr.: 81944-09-4
Category:
Natural Products Metabolic Disease Dicerothamnus rhinocerotis Plants Umbelliferae Disease Research Fields
Target:
2
2 Cited Publications
Target:
Forschungsgebiete:
FATP1-IN-2 (compound 12a), an arylpiperazine derivative, is an orally active fatty acid transport protein 1 (FATP1) inhibitor (human IC50=0.43 μM, mouse IC50=0.39 μM) .
1
1 Cited Publications
Target:
Forschungsgebiete:
FATP1-IN-1 (compound 5k) is a fatty acid transport protein 1 (FATP1) inhibitor. FATP1-IN-1 is an inhibition of recombinant human or mouse acyl-CoA synthetase activity of FATP1, with the IC50 values of 0.046 μM or 0.60 μM, respectively .
1
1 Cited Publications
Art. -Nr.: HY-RS13144
Target:
Forschungsgebiete:
SLC27A1 Human Pre-designed siRNA Set A contains three designed siRNAs for SLC27A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Target:
Forschungsgebiete:
L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an IC50 of 1.98 μM . L002 binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain, blocks histone acetylation and p53 acetylation, and inhibits STAT3 activation . L002 has the potential for hypertension-induced cardiac hypertrophy and fibrogenesis treatment .
Art. -Nr.: HY-116003
CAS. Nr.: 263399-35-5
Target:
Art. -Nr.: HY-128866
CAS. Nr.: 2332841-25-3
TBAJ-876 is an orally active diarylquinoline anti-Mycobacterium agent. TBAJ-876 regulates energy metabolism by targeting the c and ε subunits of Mycobacterium tuberculosis F-ATP synthase, exerts bactericidal activity against replicating Mycobacterium tuberculosis, and retains activity against strains carrying the Rv0678 mutation. TBAJ-876 undergoes N-demethylation in vivo to form its major active metabolite TBAJ-876-M3, which has lower lipophilicity and hERG potassium channel binding affinity. TBAJ-876 is well tolerated in BALB/c mice and significantly reduces the colony-forming units of Mycobacterium tuberculosis in the lungs. In addition, TBAJ-876 exhibits inhibitory activity against Mycobacterium abscessus, reduces bacterial loads in the lungs and spleens of infected mice, and shows no antagonistic effect when used in combination with common antibiotics. TBAJ-876 can be used in studies related to tuberculosis and Mycobacterium abscessus pulmonary diseases .
Art. -Nr.: HY-RS16240
Target:
Forschungsgebiete:
Slc27a1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Slc27a1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-162804
Target:
Forschungsgebiete:
ATP synthase inhibitor 3 (compound PT6) is an orally active inhibitor of mycobacterial F-ATP synthase (IC50=0.788 μM). ATP synthase inhibitor 3 inhibits the growth of Mycobacterium tuberculosis H37Rv strain (ATCC-27294) in vitro and depletes intracellular ATP levels at an IC50 value of 30μM .
Art. -Nr.: HY-RS27156
Target:
Forschungsgebiete:
Slc27a1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Slc27a1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-100671R
CAS. Nr.: 321695-57-2
Forschungsgebiete:
L002 (Standard) is the analytical standard of L002 (HY-100671). This product is intended for research and analytical applications. L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an IC50 of 1.98 μM . L002 binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain, blocks histone acetylation and p53 acetylation, and inhibits STAT3 activation . L002 has the potential for hypertension-induced cardiac hypertrophy and fibrogenesis treatment .
Art. -Nr.: HY-P83821A
Synonyms: VLCS; FATP2; VLACS; ACSVL1; FACVL1; hFACVL1; HsT17226
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
